Palisade Bio Stock Forward View - Simple Exponential Smoothing
| PALI Stock | USD 1.94 -0.09 -4.43% |
Predicting where Palisade Bio's stock will trade is more achievable when sentiment data complements traditional analysis. This module isolates the sentiment-driven component of price to highlight potential mispricings.
At this point in time, the 14-period RSI for Palisade Bio stands at 54, indicating neutral momentum. Momentum at the midline is a blank slate — upcoming volume and price action will likely determine the next leg.Momentum
Impartial
Oversold | Overbought |
EPS Estimate Next Quarter -0.24 | EPS Estimate Current Year -0.48 | EPS Estimate Next Year -0.23 | Wall Street Target Price 12 | EPS Estimate Current Quarter -0.27 |
This section provides headline-driven context for Palisade Bio alongside peer activity.
The Simple Exponential Smoothing forecasted value of Palisade Bio on the next trading day is projected to be 1.94 with a mean absolute deviation of 0.09 and the sum of the absolute errors of 5.57.Palisade Bio after-hype prediction price | $ 2.09 |
The sentiment panel provides context that can be compared with forecasting models and technical indicators.
Historical Fundamental Analysis of Palisade Bio can be used to cross-verify projections for Palisade Bio. The historical series provides projection context.Palisade Bio Additional Predictive Modules
Most predictive techniques to examine Palisade price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Palisade using various technical indicators. When you analyze Palisade charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Exponential Smoothing Price Forecast For the 14th of March 2026
Given 90 days horizon, the Simple Exponential Smoothing forecasted value of Palisade Bio on the next trading day is expected to be 1.94 with a mean absolute deviation of 0.09 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 5.57 .Please note that although there have been many attempts to predict Palisade Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Palisade Bio's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Palisade Bio | Palisade Bio Price Prediction | Research Analysis |
Forecasted Value
This next-day forecast for Palisade Bio uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Palisade Bio stock data series using in forecasting. Note that when a statistical model is used to represent Palisade Bio stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 112.051 |
| Bias | Arithmetic mean of the errors | -0.0022 |
| MAD | Mean absolute deviation | 0.0928 |
| MAPE | Mean absolute percentage error | 0.0496 |
| SAE | Sum of the absolute errors | 5.57 |
The mean reversion effect in Palisade Bio is stronger when the initial deviation was driven by sentiment rather than fundamental change. Identifying the root cause of Palisade Bio's price dislocation is essential before acting.
After-Hype Price Density Analysis
The probability distribution for Palisade Bio's predicted price encodes the full spectrum of outcomes, weighted by their estimated likelihood. Investors should compare this range against their personal risk tolerance before committing to Palisade Bio positions.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The news prediction model for Palisade Bio analyzes the correlation between Palisade Bio's historical headline events and same-day or next-day price movements. Palisade Bio's after-hype downside and upside margins for the prediction period are 0.10 and 8.36, respectively. Predictive accuracy varies significantly across different news categories and market regimes for Palisade Bio.
Current Value
The after-hype framework applied to Palisade Bio assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Palisade Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Palisade Bio backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Palisade Bio, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.31 | 6.30 | 0.04 | 0.03 | 9 Events | 7 Events | In 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.94 | 2.09 | 2.45 |
|
Hype Timeline
Palisade Bio is at this time traded for 1.94. The company has historical hype elasticity of 0.04, and average elasticity to hype of competition of -0.03. Palisade is expected to increase in value after the next headline, with the price projected to jump to 2.09 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 2.45%, whereas the daily expected return is at this time at 0.31%. The volatility of related hype on Palisade Bio is about 7000.0%, with the expected price after the next announcement by competition of 1.91. Palisade Bio currently holds $169 K in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest Palisade Bio is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next expected press release will be in 9 days. Historical Fundamental Analysis of Palisade Bio can be used to cross-verify projections for Palisade Bio. The historical series provides projection context.Related Hype Analysis
Sector-wide news events often affect Palisade Bio before the fundamental impact on Palisade Bio's own business becomes clear. Peer hype analysis helps investors distinguish between sector-level sentiment shifts and Palisade Bio-specific developments.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ASBP | Aspire BioPharma | -0.02 | 9 per month | 0.00 | -0.09 | 19.52 | -16.05 | 66.08 | |
| CRIS | Curis Inc | -0.04 | 9 per month | 0.00 | -0.06 | 6.48 | -7.83 | 21.52 | |
| ENTO | Entero Therapeutics | -0.23 | 6 per month | 0.00 | -0.0033 | 16.86 | -17.06 | 39.61 | |
| PCSA | Processa Pharmaceuticals | 0.15 | 8 per month | 0.00 | -0.0039 | 10.24 | -14.08 | 164.28 | |
| BCTX | Briacell Therapeutics Corp | -0.03 | 7 per month | 0.00 | -0.08 | 8.72 | -8.84 | 98.43 | |
| HOTH | Hoth Therapeutics | -0.03 | 7 per month | 0.00 | -0.02 | 7.00 | -4.76 | 14.39 | |
| LPTX | Leap Therapeutics | 0.01 | 9 per month | 6.90 | 0.14 | 25.00 | -9.43 | 65.13 | |
| CTXR | Citius Pharmaceuticals | -0.07 | 7 per month | 0.00 | -0.04 | 10.81 | -7.79 | 30.22 | |
| DARE | Dare Bioscience | -0.04 | 5 per month | 0.00 | -0.05 | 5.18 | -5.29 | 26.52 | |
| ATHA | Athira Pharma | -0.60 | 5 per month | 3.97 | 0.13 | 9.87 | -8.06 | 72.52 |
Other Forecasting Options for Palisade Bio
For both new and experienced investors in Palisade, the ability to analyze Palisade Bio's price movement is a fundamental investment skill. Price chart noise in Palisade Stock can create false signals and mislead investment decisions.Palisade Bio Related Equities
The following equities are related to Palisade Bio within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Palisade Bio against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Palisade Bio Market Strength Events
Tracking market strength indicators for Palisade Bio helps investors understand the momentum dynamics of the stock in real time. These signals support informed decisions about when to enter or exit positions in Palisade Bio for maximum return potential.
Palisade Bio Risk Indicators
Properly assessing Palisade Bio's risk indicators is a prerequisite for building reliable price forecasts. Identifying and quantifying the risks associated with Palisade Bio's allows investors to make better-informed decisions about accepting or hedging their exposure.
| Mean Deviation | 5.09 | |||
| Semi Deviation | 5.76 | |||
| Standard Deviation | 6.45 | |||
| Variance | 41.61 | |||
| Downside Variance | 36.87 | |||
| Semi Variance | 33.22 | |||
| Expected Short fall | -5.80 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Palisade Bio
Coverage intensity for Palisade Bio matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Palisade Bio Short Properties
Short sentiment tied to Palisade Bio matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 1.4 M | |
| Cash And Short Term Investments | 9.8 M |
More Resources for Palisade Stock Analysis
A comprehensive view of Palisade Bio starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Palisade Bio Stock. Key reports that frame Palisade Bio Stock are listed below:Historical Fundamental Analysis of Palisade Bio can be used to cross-verify projections for Palisade Bio. The historical series provides projection context. Our How to Invest in Palisade Bio guide provides practical guidance on trading Palisade Stock.Analysis related to Palisade Bio should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Understanding Palisade Bio includes distinguishing between market value and book value, where book value reflects Palisade's accounting equity. Palisade Bio's market capitalization is 298.41 M. With a P/B ratio of 92.96, the market values Palisade Bio well above its book equity. Enterprise value stands at 293.39 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Palisade Bio's value from its trading price, which are computed with different methods. For Palisade Bio, key inputs include a P/E ratio of 0.16, a P/B ratio of 92.96, and ROE of -2.29%. By contrast, market price reflects the level where buyers and sellers transact.